Research & Education

Implementing and Integrating a CT Screening and Smoking Cessation Program

June 30, 2016 9:00PM EDT - Recording Available

"Implementing smoking cessation in lung cancer screening settings: Opportunities and Challenges"

IASLC Lung Cancer Repeated Series: Advances in Treatment of Lung Cancer - 2016 Update

June 28, 2016 at 9:00 PM EDT - Recording Available

This live session of IASLC Lung Cancer Grand Rounds features Dr. Mark Socinski. Dr. Socinski will highlight recent data in lung cancer, presented during the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The program will focus on scientific and clinical progress most likely to impact the current management of patients with lung cancer.

2015/2016 - Optimal Utilization of Anti-Angiogenesis Therapy for NSCLC

June 23, 2016 at 7:00PM Central European Summer Time - Recording Available

This presentation will provide an overview of the concept of angiogenesis and antiangiogenesis in NSCLC as one of the "hallmarks of cancer". Available data with bevacizumab - containing regimens in patients with advanced non squamous NSCLC - will be briefly reviewed.

Update from 2016 Radiation Oncology Meetings

Thursday May 26, 2016 6:00PM Central European Summer Time - Recording Available

This program will review radiation therapy for lung cancer highlights from the recent 2016 European Lung Cancer Conference (ELCC) and European Society for Radiotherapy & Oncology (ESTRO) meetings.

IASLC European Webinar Series - 2015/2016 - Management of TKI Resistance in NSCLC

Wednesday, May 11, 2016 at 7 p.m. Central European Summer Time - Recording Available

Although patients with oncogenic-addicted NSCLC respond to targeted therapies, invariably all became refractory to the treatment as a consequence of acquired resistance. Identification of molecular mechanisms responsible for therapy failure is of crucial relevance and many new agents and strategies are currently under development.

IASLC European Webinar Series - 2015/2016 - Treatment of ALK-Positive NSCLC

Tuesday, April 19, 2016 - 7 p.m. Central European Standard Time - Recording Available

EML4 ALK inversion produces a new fusion protein kinase receptor active in 5-7% of lung adenocarcinomas. A number of small, oral molecules ALK TKI inhibitors have been developed recently. These agents have been shown to highly active and capable of substantial control of ALK driven disease. In this online educational presentation, we examine these data from recent clinical trials and address the role of ALK TKI inhibitors in current treatment paradigms.

Cell Free DNA Diagnostics in Lung Cancer Management

Tuesday, April 12, 2016 at 9 p.m. Eastern Daylight Time - Recording Available

This lecture will focus on cell free DNA in lung cancer. Topics covered will include the origin and biology of cell free DNA in this disease. Analytic and clinical validity studies, as well as evidence of clinical utility in medical decision making, will also be discussed.

Centrally Located Early-Stage Lung Cancer: When and How to Perform Stereotactic Ablative Radiotherapy (SABR)

Thursday, March 24, 2016 - 4 p.m. Central European Time - Recording Available

The IASLC Education Committee is pleased to announce the first program in the 2016 series of Live Webinars presented by the Advanced Radiation Therapy (ART) Committee. This subcommittee is focused on the development and execution of educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Suresh Senan, MD, PhD, FRCR, and Wilko Verbakel, PhD, Ir, PEDng.

IASLC European Webinar Series - 2015/2016 - Treatment of Squamous Cell NSCLC: What's New?

Thursday, March 10, 2016 - 7 p.m. Central European Time - Recording Available

Currently, the standard first-line treatment option for squamous cell NSCLC is cytotoxic chemotherapy (including cisplatin or carboplatin and a third-generation agent such as gemcitabine, taxanes, or vinorelbine.Targeted therapies have been tested in combination with cytotoxic chemotherapy but outcomes have been disappointing because of increased toxicity or lack of efficacy. Bevacizumab is contraindicated in patients with squamous histology tumours owing to a prohibitively high rate of severe pulmonary haemorrhage associated with bevacizumab treatment.

The Evolving Landscape of Small Cell Lung Cancer (SCLC) Therapy

Wednesday, March 9, 2016 at 9 p.m. Eastern Standard Time - Recording Available

In this program, Dr. Lauren Averett Byers will discuss the current treatment of small cell lung cancer (SCLC) and review emerging therapies -- including novel targeted drugs and immunotherapies that are being investigated in clinical trials and in the lab. Recent results from clinical trials and translational studies in SCLC will be discussed, as well as representative case studies.